Extraintestinal manifestations of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1982-1992

  Vavricka, Stephan R ^a,b   Schoepfer, Alain ^c   Scharl, Michael ^a   Lakatos, Peter L ^d   Navarini, Alexander ^e   Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Arthritis; Extraintestinal manifestations; Inflammatory bowel disease; Uveitis

Indexed keywords

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; AXIAL ARTHROPATHY; ENTEROPATHY; EPISCLERITIS; ERYTHEMA NODOSUM; EXTRAINTESTINAL MANIFESTATION; HEPATOBILIARY DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; MOUTH LESION; PATHOGENESIS; PERIPHERAL ARTHRALGIA; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SCLERITIS; UVEITIS; BILIARY TRACT DISEASES; COMPLICATION; EYE DISEASES; LIVER DISEASES; MUSCULOSKELETAL DISEASES; PROGNOSIS; SKIN DISEASES;

BILIARY TRACT DISEASES; EYE DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; MUSCULOSKELETAL DISEASES; PROGNOSIS; SKIN DISEASES;

EID: 84946917761     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000392     Document Type: Review

References (136)

1. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819-4831.
2. Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72:2333-2349.
3. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598-1619.
4. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123:714-718.
5. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-7236.
6. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
7. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004;10:207-214.
8. Mendoza JL, Lana R, Taxonera C, et al. [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis [Article in Spanish]. Med Clin (Barc). 2005;125:297-300.
9. Rankin GB, Watts HD, Melnyk CS, et al. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914-920.
10. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:307-327.
11. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine. 1976;55:401-412.
12. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975;68:627-635.
13. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.
14. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110-119.
15. Vavricka SR, Gantenbein C, Spoerri M, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21:1794-1800.
16. Ardizzone S, Puttini PS, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40(suppl 2):S253-S259.
17. Biancone L, Mandal A, Yang H, et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology. 1995;109:3-12.
18. Das KM, Sakamaki S, Vecchi M, et al. The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J Immunol. 1987;139:77-84.
19. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912-922.
20. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994;107:103-108.
21. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology. 1990;98:464-469.
22. Satsangi J, Grootscholten C, Holt H, et al. Clinical patterns of familial inflammatory bowel disease. Gut. 1996;38:738-741.
23. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997;112:1845-1853.
24. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585-595.
25. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274-278.
26. Mallas EG, Mackintosh P, Asquith P, et al. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut. 1976;17:906-910.
27. Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum. 2001;44:2728-2736.
28. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83:703-709.
29. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387-391.
30. Rodriguez-Reyna TS, Martinez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol. 2009;15:5517-5524.
31. Brakenhoff LK, van der Heijde DM, Hommes DW. IBD and arthropathies: a practical approach to its diagnosis and management. Gut. 2011;60:1426-1435.
32. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63:1664-1669.
33. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol. 2002;97:2688-2690.
34. Atzeni F, Ardizzone S, Bertani L, et al. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J Gastroenterol. 2009;15:2469-2471.
35. Sarzi-Puttini P, Antivalle M, Marchesoni A, et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo. 2008;60:290-295.
36. Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005;25:406-410.
37. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505-509.
38. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-1826.
39. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol. 2015;13:940-948.
40. Vanbiervliet G, Anty R, Schneider S, et al. Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab [Article in French]. Gastroenterol Clin Biol. 2002;26:295-297.
41. Singh S, Khanna S, Pardi DS, et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19:1631-1638.
42. Fries W, Giofre MR, Catanoso M, et al. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97:499-500.
43. Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53:2223-2231.
44. Lakatos PL, Lakatos L, Kiss LS, et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86(suppl 1):28-35.
45. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42:2325-2329.
46. Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832-1847.
47. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107:513-516.
48. Miner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol. 1997;92:1S-4S.
49. Kefalakes H, Stylianides TJ, Amanakis G, et al. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009;65:963-970.
50. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196-202.
51. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203-211.
52. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther. 2003;17:1371-1380.
53. Mahadevan U, Loftus EV Jr, Tremaine WJ, et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97:910-914.
54. El Miedany Y, Youssef S, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101:311-317.
55. Monsen U, Sorstad J, Hellers G, et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85:711-716.
56. Fornaciari G, Salvarani C, Beltrami M, et al. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol. 2001;15:399-403.
57. Brewerton DA, James DC. The histocompatibility antigen (HL-A 27) and disease. Semin Arthritis Rheum. 1975;4:191-207.
58. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol. 1996;8:275-287.
59. Breban M, Gombert B, Amor B, et al. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum. 1999;42:580-581.
60. Keyser FD, Mielants H, Veys EM. Current use of biologicals for the treatment of spondyloarthropathies. Expert Opin Pharmacother. 2001;2:85-93.
61. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356:1821-1822.
62. Ellman MH, Hanauer S, Sitrin M, et al. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol. 2001;7:67-71.
63. Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65:423-432.
64. Vavricka SR, Scharl M, Gubler M, et al. Which extraintestinal manifestations of IBD respond to biologics? Curr Drug Targets. 2014;15:1064-1073.
65. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine. 2008;87:281-293.
66. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol. 2005;19:603-606.
67. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26:265-273.
68. Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003;37:150-154.
69. Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, et al. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol. 2007;21:408-410.
70. Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol. 2008;5:278-281.
71. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol. 2006;31:823-824.
72. Jorizzo JL, Solomon AR, Zanolli MD, et al. Neutrophilic vascular reactions. J Am Acad Dermatol. 1988;19:983-1005.
73. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000;79:37-46.
74. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012-1023.
75. Orchard T. Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2003;5:512-517.
76. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581-585.
77. Sheldon DG, Sawchuk LL, Kozarek RA, et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg. 2000;135:564-568; discussion 568-569.
78. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA. 2000;284:1546-1548.
79. Gellert A, Green ES, Beck ER, et al. Erythema nodosum progressing to pyoderma gangrenosum as a complication of Crohn's disease. Postgrad Med J. 1983;59:791-793.
80. Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1996;34:1047-1060.
81. Powell RJ, Holbrook MR, Stevens A. Pyoderma gangrenosum and its treatment. Lancet. 1997;350:1720-1721.
82. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580-585.
83. Friedman S, Marion JF, Scherl E, et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:1-7.
84. Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol. 2011;23:50-56.
85. Arnott ID, McDonald D, Williams A, et al. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639-1646.
86. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2002;34:558-560.
87. Ferkolj I, Hocevar A, Golouh R, et al. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease. Acta Dermatovenerol Alp Pannonica Adriat. 2006;15:173-177.
88. Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology. 2002;205:278-280.
89. Juillerat P, Christen-Zach S, Troillet FX, et al. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007;215:245-251.
90. Kiran RP, O'Brien-Ermlich B, Achkar JP, et al. Management of peristomal pyoderma gangrenosum. Dis Colon Rectum. 2005;48:1397-1403.
91. Kouklakis G, Moschos J, Leontiadis GI, et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol. 2005;14:401-403.
92. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37:1108-1110.
93. Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006;5:e8.
94. Martin D, Handler T, McDermott J. Leucocytoclastic vasculitis in severe ulcerative colitis. Mil Med. 2011;176:581-583.
95. Lopez San Roman A, Bermejo F, Aldanondo I, et al. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev Esp Enferm Dig. 2004;96:420-422; 422-424.
96. Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004;49:1454-1457.
97. Singh M, Andrew SM, Lear JT. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol. 2004;29:196-197.
98. Tan MH, Gordon M, Lebwohl O, et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with antitumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930-933.
99. Triantafillidis JK, Cheracakis P, Sklavaina M, et al. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol. 2002;37:863-865.
100. Zaccagna A, Bertone A, Puiatti P, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol. 2003;13:258-260.
101. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis. 2009;15:803-806.
102. Pomerantz RG, Husni ME, Mody E, et al. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157:1274-1275.
103. Zold E, Nagy A, Devenyi K, et al. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: two birds with one stone. World J Gastroenterol. 2009;15:2293-2295.
104. Mimouni D, Anhalt GJ, Kouba DJ, et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813-816.
105. Thrash B, Patel M, Shah KR, et al. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68:211 e211-233; quiz 244-216.
106. Becuwe C, Delaporte E, Colombel JF, et al. Sweet's syndrome associated with Crohn's disease. Acta Derm Venereol. 1989;69:444-445.
107. Benton EC, Rutherford D, Hunter JA. Sweet's syndrome and pyoderma gangrenosum associated with ulcerative colitis. Acta Derm Venereol. 1985;65:77-80.
108. Banet DE, McClave SA, Callen JP. Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease. J Rheumatol. 1994;21:1766-1768.
109. Treton X, Joly F, Alves A, et al. Azathioprine-induced Sweet's syndrome in Crohn's disease. Inflamm Bowel Dis. 2008;14:1757-1758.
110. Ali M, Duerksen DR. Ulcerative colitis and Sweet's syndrome: a case report and review of the literature. Can J Gastroenterol. 2008;22:296-298.
111. Kemmett D, Hunter JA. Sweet's syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol. 1990;23:503-507.
112. Vavricka SR, Manser CN, Hediger S, et al. Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013;19:2768-2777.
113. Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol. 1982;14:356-360.
114. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34:1146-1150.
115. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006;33:231-237.
116. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-1453.
117. Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89:533-536.
118. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308-314.
119. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-296.
120. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
121. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982-989.
122. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860-864.e862.
123. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319-324.
124. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447-2451.
125. Mintz R, Feller ER, Bahr RL, et al. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135-139.
126. Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1655-1667.
127. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100:1319-1323.
128. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991;11:31-39.
129. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79:200-206.
130. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26:31-41.
131. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107-114.
132. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33:854-862.
133. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48-54.
134. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-96.
135. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis. 2005;11:62-72.
136. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997;336:691-695.